202 related articles for article (PubMed ID: 35970682)
21. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.
Smith ZL; Christodouleas JP; Keefe SM; Malkowicz SB; Guzzo TJ
BJU Int; 2013 Jul; 112(1):13-25. PubMed ID: 23356411
[TBL] [Abstract][Full Text] [Related]
22. Organ-sparing surgery in urology: partial cystectomy.
Knoedler J; Frank I
Curr Opin Urol; 2015 Mar; 25(2):111-5. PubMed ID: 25581537
[TBL] [Abstract][Full Text] [Related]
23. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.
Koga F; Kihara K
Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269
[TBL] [Abstract][Full Text] [Related]
24. Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Konieczkowski DJ; Efstathiou JA; Mouw KW
Hematol Oncol Clin North Am; 2021 Jun; 35(3):567-584. PubMed ID: 33958151
[TBL] [Abstract][Full Text] [Related]
25. Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer.
de Angelis M; Basile G; Scornajenghi CM; Asero V; Del Giudice F; Moschini M
Curr Opin Urol; 2023 Sep; 33(5):354-359. PubMed ID: 37395512
[TBL] [Abstract][Full Text] [Related]
26. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
27. Bladder-sparing approaches to invasive disease.
Efstathiou JA; Zietman AL; Kaufman DS; Heney NM; Coen JJ; Shipley WU
World J Urol; 2006 Nov; 24(5):517-29. PubMed ID: 17082940
[TBL] [Abstract][Full Text] [Related]
28. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.
Kanady KE; Shipley WU; Zietman AL; Kaufman DS; Althausen AF; Heney NM
Semin Surg Oncol; 1997; 13(5):359-64. PubMed ID: 9259092
[TBL] [Abstract][Full Text] [Related]
29. Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.
El-Taji OM; Alam S; Hussain SA
Curr Treat Options Oncol; 2016 Mar; 17(3):15. PubMed ID: 26942590
[TBL] [Abstract][Full Text] [Related]
30. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future.
Kimura T; Ishikawa H; Kojima T; Kandori S; Kawahara T; Sekino Y; Sakurai H; Nishiyama H
Jpn J Clin Oncol; 2020 Sep; 50(10):1097-1107. PubMed ID: 32895714
[TBL] [Abstract][Full Text] [Related]
31. Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer.
Broughman JR; Vuong W; Mian OY
Curr Treat Options Oncol; 2020 Nov; 22(1):3. PubMed ID: 33230599
[TBL] [Abstract][Full Text] [Related]
32. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review.
Hamad J; McCloskey H; Milowsky MI; Royce T; Smith A
Int Braz J Urol; 2020; 46(2):169-184. PubMed ID: 31961624
[TBL] [Abstract][Full Text] [Related]
33. [Organ-sparing treatment of bladder cancer].
Niedworok C; Shaleva A; Rübben H; Stenzl A
Urologe A; 2016 May; 55(5):609-14. PubMed ID: 27119956
[TBL] [Abstract][Full Text] [Related]
34. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
[TBL] [Abstract][Full Text] [Related]
35. [Muscle invasive bladder cancer and bladder preservation protocols. Where are we?].
Domínguez Escrig JL
Arch Esp Urol; 2020 Dec; 73(10):986-995. PubMed ID: 33269717
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
[TBL] [Abstract][Full Text] [Related]
37. Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer.
Ericson KJ; Murthy PB; Bryk DJ; Ramkumar RR; Broughman JR; Khanna A; Mian OY; Campbell SC
Clin Adv Hematol Oncol; 2019 Dec; 17(12):697-707. PubMed ID: 31851158
[TBL] [Abstract][Full Text] [Related]
38. [Trimodal, organ-preserving treatment of organ-confined, muscle-invasive bladder cancer].
Ágoston P; Jorgo K; Kocsis ZS; Varga L; Gesztesi L; Takácsi-Nagy Z; Polgár C
Magy Onkol; 2021 Dec; 65(4):319-328. PubMed ID: 34874363
[TBL] [Abstract][Full Text] [Related]
39. Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
Wettstein MS; Rooprai JK; Pazhepurackel C; Wallis CJD; Klaassen Z; Uleryk EM; Hermanns T; Fleshner NE; Zlotta AR; Kulkarni GS
PLoS One; 2019; 14(4):e0216255. PubMed ID: 31034504
[TBL] [Abstract][Full Text] [Related]
40. The current status of bladder preservation in the treatment of muscle invasive bladder cancer.
Kim HL; Steinberg GD
J Urol; 2000 Sep; 164(3 Pt 1):627-32. PubMed ID: 10953112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
